SREBF1 and breast carcinoma: In breast cancer patients, increased expression of the oncoprotein HBXIP, which is associated with decreased overall and progression-free survival, exerts its effects through the upregulation of SREBP-1c and activating LXR (liver X receptor) in a ligand-independent manner.